Immunovant (IMVT) Q2 2025 earnings summary

Executive summary

• IMVT-1402 advanced significantly in 2024, with five INDs cleared across multiple autoimmune indications, enabling rapid advancement of pivotal trials in Graves' disease and difficult-to-treat rheumatoid arthritis, and setting up for trials in ten indications by March 2026.

• Strong clinical data for IMVT-1402 and batoclimab, including deep, dose-dependent IgG lowering and favorable safety, support best-in-class potential and robust mechanistic rationale for FcRn inhibition.

• Pivotal trials are designed for high unmet need populations, leveraging biomarker-driven strategies and innovative trial designs to accelerate data generation and regulatory approval.

• Batoclimab continues in Phase 3 trials for myasthenia gravis, thyroid eye disease, and CIDP, with top-line data expected in 2025; IMVT-1402 development leverages batoclimab data and in-class competitor insights.

• Melanie Gloria appointed Chief Operating Officer, bringing extensive late-stage drug development experience.

Financial highlights

• Net loss for Q2 FY2024 was $109.1 million ($0.74/share), up from $58.7 million ($0.45/share) year-over-year, driven by increased R&D and G&A expenses; six-month net loss was $196.3 million ($1.34/share).

• Cash and cash equivalents totaled $472.9 million as of September 30, 2024, supporting ongoing and planned clinical development activities.

• R&D expenses for Q2 FY2024 were $97.3 million, up from $48.0 million in Q2 FY2023, mainly due to IMVT-1402 trial preparations and higher batoclimab clinical costs.

• G&A expenses for Q2 FY2024 were $18.5 million, up from $13.8 million in Q2 FY2023, driven by higher personnel, legal, and IT costs.

• No product revenue generated; company remains reliant on equity financing and has not issued any ATM shares under its $150 million program.

Outlook and guidance

• On track to initiate four to five potentially registrational trials with IMVT-1402 by March 31, 2025, and clinical trials in ten indications by March 31, 2026.

• Top-line data from batoclimab trials in MG and CIDP expected by March 31, 2025; TED trial data expected in H2 2025.

• Existing cash and cash equivalents are expected to fund operating expenses and capital requirements for at least the next 12 months and into the long term.

• Anticipates continued increases in R&D expenses as clinical programs expand for IMVT-1402 and batoclimab.

• Focused on expanding into additional autoimmune indications as scientific and clinical evidence supports.